Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune

This page shows the latest Adaptimmune news and features for those working in and with pharma, biotech and healthcare.

Roche builds on Immunocore ImmTAC deal

Roche builds on Immunocore ImmTAC deal

The new deal comes at an interesting time, as Immunocore's Oxford 'twin' biotech Adaptimmune has recently seen its share price plunge after the failure of its MAGE-A4 and

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific peptide-enhanced affinity receptor T cell immunotherapies in solid and haematological cancers.

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    526. Adaptimmune/ GSK. Co-development and option. TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2).

  • Pharma deals during June 2014 Pharma deals during June 2014

    Of course the growth area within oncology is the immunological approach and GSK closed a $350m co-development and option deal with Adaptimmune. ... Adaptimmune develops TCR engineered T-cells and the agreement focuses on co-development around the cancer

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Adaptimmune appoints Lawrence Alleva to its board Adaptimmune appoints Lawrence Alleva to its board

    Dr Jonathan Knowles, chairman of Adaptimmune, said: “I am delighted that such a high caliber individual as Larry Alleva has agreed to join our board of directors. ... Alleva's appointment follows a brace of recent senior hires that saw Adaptimmune

  • Adaptimmune appoints former GSK executives Adaptimmune appoints former GSK executives

    Dr Amado said: “I am pleased to be joining Adaptimmune at this exciting time. ... Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics